Cagrilintide
Cagrilintide is a long-acting synthetic analog of amylin — a peptide co-secreted with insulin by pancreatic beta cells that reduces food intake by slowing gastric emptying, suppressing glucagon, and signaling satiety through area postrema receptors. With a half-life of approximately 7 days (enabled by fatty acid conjugation), it is suitable for once-weekly dosing and is being developed in combination with semaglutide 2.4 mg as 'CagriSema' (Novo Nordisk). Phase 2 data for CagriSema showed up to ~15% weight loss at 32 weeks; the REDEFINE phase 3 program is evaluating the combination at higher doses with longer follow-up. Cagrilintide monotherapy produces modest weight loss; the combination's rationale is complementary and non-overlapping mechanisms — amylin-mediated gastric and central effects combined with GLP-1 mediated effects on appetite and glucose.
Evidence last reviewed: 04 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
Cagrilintide shows significant weight loss and glycemic control in phase 3 trials, particularly in combination with semaglutide. While the evidence is strong, further long-term studies are needed to fully understand its efficacy and safety profile.
Weight loss & glycemic control — late-stage trial report (type 2 diabetes)Adults with type 2 diabetes (CagriSema vs semaglutide) · Late-stage trial (news report; now superseded by peer-reviewed NEJM publication above)Low
Reuters news report (February 2026) described CagriSema outperforming semaglutide in a late-stage diabetes trial; this is now confirmed by the peer-reviewed REDEFINE 2 NEJM paper (see above).
Body weight reduction (phase 3 — REDEFINE 1, overweight/obesity without diabetes)Adults with overweight/obesity (without diabetes), n=3417 randomized · Randomized, double-blind, placebo-controlled and active-controlled phase 3a trialHigh
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) produced an estimated mean body-weight reduction of -20.4% vs -3.0% with placebo at week 68 (P<0.001), superior to either component alone. GI adverse events were common (majority transient & mild-to-moderate). Published in NEJM 2025.
Body weight & glycemic control (phase 3 — REDEFINE 2, type 2 diabetes)Adults with overweight/obesity and type 2 diabetes (n=1206 randomized) · Randomized, double-blind, placebo-controlled phase 3a trialHigh
CagriSema produced mean weight loss of -13.7% vs -3.4% with placebo at week 68, & 73.5% of patients achieved HbA1c ≤6.5% vs 15.9% with placebo. GI adverse events in 72.5% of CagriSema group (mostly transient/mild-moderate). Published in NEJM 2025.
Clinical Weight Loss Protocol
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).